Jignesh S Kotecha
☆    

India,
2019-05-12 18:53

Posting: # 20280
Views: 656
 

 Abridged application for modified release forms [Regulatives / Guidelines]

We are developing a prolonged release tablet for Europe market. This product has got single strength. The therapeutic doses is achieved with this single strength by increasing the number of tablets per day in three divided doses. These doses should be attained slowly, by step-wise increase by one tablet every two weeks.

We are required to conduct a single dose fasting, single dose fed and multiple dose study in fed condition. Since this product has single strength and dose is increased to therapeutic level step-wise, can we conduct the multiple dose study at given strength considering it as a sensitive strength?


Edit: Please follow the Forum’s Policy[Helmut]
Activity
 Admin contact
20,122 posts in 4,245 threads, 1,383 registered users;
online 16 (3 registered, 13 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 16:07 CET

Genius is that which forces
the inertia of humanity to learn.    Henri Bergson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5